In-Press Preview Research ArticleImmunologyOncology Free access | 10.1172/JCI98509
Find articles by S. Alam, I. in: JCI | PubMed | Google Scholar
Find articles by T. Mayer, A. in: JCI | PubMed | Google Scholar
Find articles by Sagiv-Barfi, I. in: JCI | PubMed | Google Scholar
Find articles by Wang, K. in: JCI | PubMed | Google Scholar
Find articles by Vermesh, O. in: JCI | PubMed | Google Scholar
Find articles by K. Czerwinski, D. in: JCI | PubMed | Google Scholar
Find articles by M. Johnson, E. in: JCI | PubMed | Google Scholar
Find articles by L. James, M. in: JCI | PubMed | Google Scholar
Find articles by Levy, R. in: JCI | PubMed | Google Scholar
Find articles by S. Gambhir, S. in: JCI | PubMed | Google Scholar
First published March 29, 2018 - More info
In situ cancer vaccines are under active clinical investigation due to their reported ability to eradicate both local and disseminated malignancies. Intratumoral vaccine administration is thought to activate a T cell mediated immune response, which begins in the treated tumor and cascades systemically. We describe a positron emission tomography tracer (64Cu-DOTA-AbOX40) that enabled non-invasive and longitudinal imaging of OX40, a cell surface marker of T cell activation. We report the spatiotemporal dynamics of T cell activation following in situ vaccination with CpG oligodeoxynucleotide, in a dual tumor bearing mouse model. We demonstrate that OX40 imaging could predict tumor responses at day 9 post treatment based on tumor tracer uptake at day 2, with higher accuracy than both anatomical and blood-based measurements. These studies provide key insights into global T cell activation following local CpG treatment and indicate that 64Cu-DOTA-AbOX40 is a promising candidate for monitoring clinical cancer immunotherapy strategies.